NeuroPace Inc. is a commercial-stage medical device company. It is focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in MOUNTAIN VIEW, Calif.
| Revenue (Most Recent Fiscal Year) | $79.91M |
| Net Income (Most Recent Fiscal Year) | $-27.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.10 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 17.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -29.42% |
| Net Margin (Trailing 12 Months) | -29.42% |
| Return on Equity (Trailing 12 Months) | -190.84% |
| Return on Assets (Trailing 12 Months) | -25.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.63 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.46 |
| Inventory Turnover (Trailing 12 Months) | 1.68 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.74 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 32.80M |
| Free Float | 25.52M |
| Market Capitalization | $429.99M |
| Average Volume (Last 20 Days) | 0.47M |
| Beta (Past 60 Months) | 2.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |